Supreme Court Upholds Medicare Drug Price Negotiation Program Amid Pharma Industry Challenge
Supreme Court Hands Major Blow To Big Pharma's Fight Against Biden-Era Medicare Drug Pricing Law
Benzinga
Image: Benzinga
The U.S. Supreme Court has declined to hear a challenge from major pharmaceutical companies against the Medicare drug price negotiation program established under the Inflation Reduction Act. This decision leaves in place lower-court rulings that favor the federal government, allowing the Centers for Medicare & Medicaid Services to negotiate prices for high-cost medications.
- 01Pharmaceutical companies including Novo Nordisk and AstraZeneca argued that the program imposes unconstitutional price controls.
- 02The Medicare negotiation framework allows CMS to negotiate prices for certain high-cost drugs, with penalties for non-compliance.
- 03The first negotiated prices for ten drugs took effect this year, with 15 additional drugs selected for negotiation.
- 04The Biden administration's drug pricing framework is projected to save approximately $529 billion over the next decade.
- 05Senator Peter Welch has expressed support for advancing the administration's drug pricing model in Congress.
Advertisement
In-Article Ad
On Monday, the U.S. Supreme Court declined to hear appeals from several major pharmaceutical companies, including Novo Nordisk and AstraZeneca, regarding the Medicare drug price negotiation program established by the Inflation Reduction Act. This ruling upholds lower-court decisions that support the federal government's ability to negotiate prices directly with drug manufacturers for high-cost medications covered under Medicare. The companies contended that the program represents government-imposed price controls that threaten innovation and violate constitutional rights. Under this framework, the Centers for Medicare & Medicaid Services (CMS) can negotiate prices, and companies that refuse to comply may face significant penalties. The first negotiated prices for ten drugs were implemented this year, with an additional 15 drugs selected for negotiation in the latest cycle. The Biden administration estimates that this program could save Medicare approximately $8.5 billion in 2024 and generate $529 billion in savings over the next decade. Senator Peter Welch has voiced his support for advancing the drug pricing model in Congress, reflecting a broader concern over high prescription drug costs in the U.S.
Advertisement
In-Article Ad
This ruling is significant for Medicare beneficiaries, as it aims to lower their prescription drug costs through negotiated pricing.
Advertisement
In-Article Ad
Reader Poll
Do you support the Medicare drug price negotiation program?
Connecting to poll...
More about Centers for Medicare & Medicaid Services
Read the original article
Visit the source for the complete story.